Search Result

Basic Information

Classification Information

Regulatory Mechanism		Biological Function		Clinical Application
TF		Immune		Survival
Enhancer		Apoptosis		Drug
Variant		Cell Growth		Circulating
MiRNA		EMT		Metastasis
Methylation		Coding Ability		Recurrence

Cancer&Entry Information

Cancer Name	hepatocellular carcinoma
ICD-0-3	C22.0
Methods	qPCR, Western blot, e luciferase reporter assay, etc.
Sample	Human HCC cell lines (ie, Bel-7402, HepG2, Hep3b, QGY7703, SMMC-7721). HCC tissues.
Expression Pattern	up-regulated
Function Description	In conclusion, the miR-193a-3p targeted by lncRNA H19 tended to master the chemo- and radio- resistances of HCC by modulation of PSEN1, which might assist in supplying novel biomarkers to improve the treatment efficacy for HCC for that chemo- and radio-resistances themselves could make the efficacies be poor. The following drugs were taken into application, including docetaxel (DT) (Sanofi-Aventis, Paris, France), paclitaxel (Pt) (Taijipharmaceutical Co. Xi'an, China), vinorelbine (Vb) (Pierre Fabre, Castres, France), and 5-fluorouracil (5-Fu) (Macklin, Shanghai, China). The restrained lncRNA H19 and over-expressed miR-193a-3p expressions tended to significantly elevate the survival rate and proliferation of Bel-7402 cells, when they were exposed to radiation and subject to chemo-therapies. PSEN1 appeared to be subject to the modification of lncRNA H19 and miR-193a-3p in its acting on the survival rates and proliferative abilities of HCC cells. The lncRNA H19/miR-193a-3p/PSEN1 axis could be regarded as the treatment targets for HCC, so as to further improve the treatment efficacy of chemo- and radio-therapies for HCC.
Pubmed ID	29968942
Year	2018
Title	The LncRNA H19/miR-193a-3p axis modifies the radio-resistance and chemotherapeutic tolerance of hepatocellular carcinoma cells by targeting PSEN1.

External Links